01953oam 2200457 450 991070472900332120131028114013.0(CKB)5470000002444437(OCoLC)855764785(EXLCZ)99547000000244443720130814d2013 ua 0engurbn||||a||||txtrdacontentcrdamediacrrdacarrierReview of the proposed generic drug and biosimilars user fees and further examination of drug shortages hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Twelfth Congress, second session, February 9, 2012Washington :U.S. Government Printing Office,2013.1 online resource (iv, 194 pages) illustrationsTitle from title screen (viewed on Aug. 14, 2013).Paper version available for sale by the Superintendent of Documents, U.S. Government Printing Office."Serial no. 112-114."Includes bibliographical references.Review of the proposed generic drug and biosimilars user fees and further examination of drug shortages Drug approvalUnited StatesGeneric drugsGovernment policyUnited StatesBiologicalsGovernment policyUnited StatesDrug accessibilityUnited StatesFees, AdministrativeUnited StatesDrug approvalGeneric drugsGovernment policyBiologicalsGovernment policyDrug accessibilityFees, AdministrativeGPOGPOGPOBOOK9910704729003321Review of the proposed generic drug and biosimilars user fees and further examination of drug shortages3535166UNINA